"You can stay forever." For Episode 253, Brandon and Thomas tackle the works of Richard Curtis. Listen as they discuss his life and his filmography, including NOTTING HILL, LOVE ACTUALLY, ABOUT TIME, and much more. Find out what inspired Curtis' films and how he became one of the most prolific rom-com creators. Check out our new Patreon Page: https://www.patreon.com/cinenation Contact Us: Facebook: @cinenation Instagram: @cinenationpodcast Twitter: @CineNationPod TikTok: @cinenation Letterboxd: CineNation Podcast E-mail: firstname.lastname@example.org
Guest host Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss several crucial studies that will be presented at the 2023 ASCO Genitourinary Cancers Symposium, including ARASENS, TRITON3, and others in prostate cancer, as well as novel therapies in mRCC and urothelial carcinoma. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a medical oncologist and the clinical program director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia. Today we will be discussing key abstracts in genitourinary oncology that will be featured at the 2023 ASCO Genitourinary Cancers Symposium. Our full disclosures are available in the show notes, and disclosures for all guests on the podcast can be found on our transcripts at asco.org/podcasts. Jeanny, it is great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me. Dr. Neeraj Agarwal: So Jeanny, let's begin with Abstract 15 on the update on the ARASENS trial, which Dr. Maha Hussain will present [at the meeting]. In March ‘22, as we know, almost a year ago, the results of the ARASENS trials were published in the New England Journal of Medicine. Darolutamide, which is an AR signaling inhibitor plus androgen deprivation therapy plus docetaxel chemotherapy, significantly reduced the risk of death by 32.5% versus placebo plus ADT plus docetaxel. The effect of triplet therapy, including darolutamide on overall survival, was consistent across prespecified subgroups. However, survival outcomes by disease volume were not reported at the time. Can you please tell us about Abstract 15? Dr. Jeanny Aragon-Ching: Yeah, thank you so much, Neeraj, I would be happy to. So, this new data is actually very crucial for all clinicians. The title of this abstract is “Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study.” So, as a quick reminder, in this trial, patients were randomized 1:1 to the standard dose of darolutamide 600 milligrams twice daily or placebo with ADT and docetaxel in the metastatic hormone-sensitive prostate cancer setting. Now remember, too, high volume disease was defined per the charted criteria, which is visceral metastases and/or four or more bone lesions, of which at least one or more has to be beyond the vertebral column or pelvis. 8And high-risk disease was actually defined per the LATITUDE criteria, which is any two or more of the following three factors: Gleason scores eight or more, bone lesions that are three or more, and the presence of measurable visceral metastases. Of all the 1,305 patients, 77% of them were actually classified as having high-volume disease, and 70% of them had high-risk disease. So, in both of these high-volume and low-volume disease patients, the triplet therapy darolutamide, ADT, and docetaxel actually improved overall survival and hazard ratio was 0.69 and 0.68, respectively. Compared to the placebo and ADT, and docetaxel arm. So overall survival improvement was also significant in patients across all risk, high-risk, or low-risk disease. Dr. Neeraj Agarwal: So, Jeanny, this is great news. So, the main message from this abstract for our audience is that triplet therapy of darolutamide plus docetaxel plus ADT is more efficacious than the doublet of ADT plus docetaxel chemotherapy, regardless of disease volume or risk status. One important caveat I would like to note is that triplet therapy with the darolutamide was not compared with the doublet therapy of ADT plus darolutamide or any androgen receptor signaling inhibitor such as abiraterone or apalutamide or enzalutamide, all of which have shown benefit consistently, regardless of volume status, and in the case of abiraterone, also in the context of high-risk disease setting, as we saw in the LATITUDE trial. Dr. Jeanny Aragon-Ching: Absolutely. I agree with that, Neeraj. Those are important points to consider. Now, moving on to a different setting in prostate cancer across the disease continuum, let's discuss Abstract 18, titled “Rucaparib for Metastatic Castrate-Resistant Prostate Cancer.” This is TRITON3 entering overall survival and efficacy of rucaparib versus docetaxel or second-generation engine pathway inhibitor therapy, which will provide us with some additional data regarding overall survival. Neeraj, based on this new abstract, can you tell us more about TRITON3, which will be presented by Dr. Alan Bryce and colleagues from the Mayo Clinic Arizona? Dr. Neeraj Agarwal: Of course. So TRITON3 is a randomized multicenter open-label phase 3 trial where rucaparib was compared with the physician choice of docetaxel chemotherapy or abiraterone or enzalutamide in those patients who had not received chemotherapy in the metastatic castration-resistant prostate cancer setting, and they had to be progressing on a prior androgen receptor signaling inhibitor in any setting prior. So, they just had to have disease progression either in the hormone-sensitive setting or CRPC setting on one of the AR inhibitors, and they had to have a BRCA1, BRCA2, or ATM alteration. So, in this context, these patients were randomized to rucaparib versus physician's choice of agent, which could again be docetaxel chemotherapy, abiraterone, or enzalutamide. So, OS maturity is 54% in BRCA group and 59% in the intention to treat population. In BRCA1 and BRCA2 populations, radiographic PFS, which was the primary endpoint, was 11.2 months in rucaparib group and 6.4 months in the physician choice arm. In the intention to treat population where you include all patients BRCA plus ATM patients, ATM positive patients. Radiographic PFS was 10 months almost versus 6.4 months with standard of care. And both were statistically significant as well as clinically meaningful improvement in the radiographic progression-free survival with rucaparib over physician's choice of either docetaxel or enzalutamide, or abiraterone. I would like to note that most frequent toxicity which we see with this group of agents is most frequent grade III or more toxicity was anemia, which was present in approximately 24% patients treated with rucaparib. Dr. Jeanny Aragon-Ching: Yeah. This is a really exciting update, Neeraj. What do you think is the key takeaway from this abstract? Dr. Neeraj Agarwal: The key takeaway is that TRITON3 trial met its primary endpoint, and rucaparib significantly improves radiographic progression-free survival in BRCA mutation-positive patients or BRCA ATM-positive patients. Overall survival is still immature, and these results further establish rucaparib as one of the standard of care options in those patients who have metastatic CRPC with prior treatment with the AR signaling inhibitor and who harbor one of the BRCA mutations or BRCA NAT mutations. So, Jeanny, before moving on to the renal cell carcinoma section in this podcast, there is an Abstract in prostate cancer talking about correlation between the source of funding and disparities among patients with advanced prostate cancer. So, I'm referring to that Abstract 40, titled “Source of Funding and Enrollment Disparity in Prostate Cancer Clinical Trials.” I thought this was an interesting abstract. Could you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in Abstract 40, Dr. Riaz and Dr. Bryce, and colleagues actually looked at phase II and III clinical trials that involved prostate cancer patients that reported on patients with age by 65 years, and they got the data from the MEDLINE and Embase databases. Trials recruiting from the United States were considered eligible for analysis by race and ethnicity. So, in terms of race and ethnic enrollment, they found that black patients were significantly underrepresented in the industry's funded trials. Notably, no significant disparity was observed in the US government-funded trials, but Hispanics were also significantly underrepresented in industry-funded clinical trials. However, no significant disparity was seen in terms of older adults overall and by funding sources. Remarkably, Black patients' representation in industry-funded prostate cancer trials has actually decreased over the last three decades. Dr. Neeraj Agarwal: That's concerning. So, what is your key takeaway from this trial, Jeanny? Dr. Jeanny Aragon-Ching: The key message here is that Black and Hispanic men with prostate cancer are significantly less likely to be included in industry-sponsored clinical trials. A bigger concern is that black patients' representation actually continues to decline over time. So these results warrant a really more proactive role by regulatory bodies to ensure that a proportional representation of minorities in the industry trials, which in turn will make these results more applicable to a wider entire population of men with prostate cancer. Dr. Neeraj Agarwal: Thanks, Jeanny. Let's move on to renal cell carcinoma. I saw some innovative research correlating the efficacy of immune checkpoint inhibitors with the time of the day these checkpoint inhibitors were administered. So, interestingly, there were two studies from two different groups of investigators showing very similar results. Please tell us about this innovative research correlating outcomes with immune checkpoint inhibitors with the time of the day these medicines or these drugs were infused into the patients. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. I think they're very exciting and interesting. So there's actually two abstracts, so Abstract 681 and 678, which we, of course, can discuss separately. So, let's probably start first with Abstract 678. Neeraj, do you want to explain to us further about this abstract? Dr. Neeraj Agarwal: Yes. When our center participated in that abstract, which was led by Dr. Nazli Dizman from Yale University, Dr. Dizman and colleagues examined the relationship between the time of the administration of immune checkpoint inhibitors, or ICIs, as we call them, during the time of the day, and outcomes in patients with metastatic renal cell carcinoma. So, I'd like to point out that previously Dr. Qian and colleagues reported an association between the time of day of immunotherapy infusion and survival outcomes in patients with metastatic melanoma. In this study, Dr. Dizman and colleagues, which included our center also, patients with metastatic RCC who received nivolumab with or without ipilimumab– so these patients all received either nivolumab alone or without ipilimumab. And patients who received less than 25% of infusion after 4:30 pm. were assigned to the early-time of infusion group. So, if they have received less than 25% infusion of these immunotherapies after 04:30 pm in the evening, they belong to the early infusion group, and the rest were assigned to the late infusion group. In the univariate analysis, numerically higher objective responses and time to treatment failure were observed in the early infusion group compared to the late infusion group. So, differences were 33% versus 25% in objective responses in early versus late infusion group. If you look at time to treatment failure, 8.3 months versus 4.4 months in early versus late infusion group. In the multivariate models, which took into account the clinical characteristics such as age, gender, line of treatment, IMDC risk category, histological subtypes, there was a trend towards improved outcomes in those who received these infusions with ICIs early in the day. So, Dr. Dizman concluded that larger randomized and controlled investigations are warranted to examine the impact of this chronal modulation, if you will, on the efficacy of immune checkpoint inhibitors in metastatic RCC sets. Dr. Jeanny Aragon-Ching: Yeah, this is very interesting data, Neeraj. And that actually resonates closely with this other abstract by Fernandez Manias and colleagues in Abstract 681. So, in this abstract, the primary outcome was overall survival, but they did look at other secondary endpoints like time on treatment, time to the next treatment, and overall response rates. Now, because of the small number of events, the authors actually focused on just patients who received second-line immune checkpoint inhibitors. And what they did was they looked at patients who received overall more than 20% of their infusions after 04:30 pm, and they found that those who did receive actually fewer infusions had a significantly shorter time on treatment and had a worse overall survival. And similar results were seen when they looked at those who got more than 50% of their dose of checkpoint inhibitors that were administered after 04:30 pm, so interestingly enough, there was a 16% increase in the risk of death for each 10% increment of checkpoint infusion after 04:30 pm. So the key message here is that administration of checkpoint inhibitors after 04:30 pm is associated, unfortunately, with inferior outcomes. Now, these results should, of course, be further considered in the organization overall of the outpatient clinic as it can impact patient survival and outcomes. Dr. Neeraj Agarwal: Very interesting. So similar results from two independent groups of investigators from two different continents obviously made this research area very appealing and pertinent. Ideally, I think these results should be validated prospectively, but that will take time. But investigators who have already lagged multiple phase III trials should explore validating these results in the last phase 3 trials which have already been reported and where the data on the timing of infusion is available. Once validated, I think these results may profoundly influence how we organize, as you said, Jeanny, the outpatient scheduling of these checkpoint therapy infusions compared to those who are not checkpoint inhibitors. I think this is going to have very interesting data overall, no doubt. Before moving onto bladder cancer, I would like to discuss an important abstract related to testicular cancer patients titled “Longitudinal Evaluation of Plasma MicroRNA-371 to Detect Minimal Residual Disease and Early Relapse of Germ Cell Tumors.” Could you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this is a very interesting up-and-coming Abstract, it's number 407, which will be presented by Dr. Lucia Nappi and colleagues. In this study, clinical patients with stage I germ cell tumor with available plasma samples after they underwent radical orchiectomy were all included. So, they looked at sensitivity, specificity, negative, positive predictive values, an area under the curve in predicting tumor recurrence, and they evaluated the microRNA-371, I'll just call it and truncate it as miR-371, and compared the same operating characteristics of current gold standard diagnostic tests. Relapse-free survival was correlated to post-orchiectomy miR-371 status, which could be either positive or negative. So, at a median follow-up of 41 months, 101 patients with clinical stage one germ cell tumor were included. About 35% of them experienced a disease relapse during that time of follow-up. Now, what they found was miR-371 was positive in about 63% of the relapsed patients, and the miR-371 positivity preceded clinically evident disease by a median of about three months. The specificity and positive predictive values were 100%, sensitivity was like 63%, and negative predictive value was 83.5%, so very high. No false positive results were seen. And, the authors reported that the recurrence-free survival of the patients who had positive post-orchiectomy miR-371 was significantly shorter compared to those patients who had a negative biomarker for the miR-371. So, they concluded that the miR-371 sensitivity correlated with the tumor burden, time between tumor relapse, the microRNA testing, and histology. It was notably a little bit more sensitive in non-seminomas compared to those who had seminoma. Dr. Neeraj Agarwal: Interesting findings, indeed. So, Jeanny, what is the take-home message from this abstract? Dr. Jeanny Aragon-Ching: Yeah, so I think the key takeaway is that microRNA-371 seems to be a good test, like a biomarker for predicting disease relapse in patients with early-stage germ cell tumor. So, additionally, its high specificity and positive predictive value in predicting relapse could really be used and utilized to guide adjuvant therapy, selections, and decisions after orchiectomy. Further validation in other studies, such as swab 1823, are currently ongoing or planned to validate its clinical utility. So Neeraj, moving on to bladder cancer, the last abstract I'd like to mention before we wrap up the podcast is Abstract 563, titled “Utility of ctDNA in Predicting Outcome and Pathological Complete Response in Patients with Bladder Cancer as a Guide for Selective Bladder Preservation Strategies.” Neeraj, can you tell us more about this abstract? Dr. Neeraj Agarwal: Sure. So, this study was led by Dr. Lars Dyrskjøt. He and colleagues evaluated the prognostic value of circulating tumor DNA, or ctDNA, in predicting recurrence in a cohort of 68 patients with muscle-invasive bladder cancer who received new adjuvant chemotherapy prior to cystectomy. So ctDNA was analyzed two times at baseline before new adjuvant chemotherapy and then before surgery or before cystectomy. So, patients had ctDNA assessed before neoadjuvant chemotherapy and then before cystectomy after completion of new adjuvant chemotherapy. At baseline, of the 64 patients, around 60% were ctDNA negative, and 40% were positive for ctDNA. So of those patients who were ctDNA negative, 84% achieved pathologic complete response, while in those who tested ctDNA positive, only 35% achieved their pathologic complete response after surgery. Prior to surgery, 84% of patients were ctDNA negative, and 81% achieved pathologic complete response. While none of the ctDNA-positive patients who were positive before surgery and after neoadjuvant chemotherapy, none of them achieved pathologic complete response, which translates into a positive predictive value of 100% and a negative predictive value of 81% for this test. So based on both ctDNA time points, the probability of ctDNA negative patients to achieve a pathologic complete response was significantly higher than ctDNA positive patients. At a median follow-up of 59 months, ctDNA-positive patients without pathologic complete response demonstrated significantly lower recurrence-free survival and overall survival compared to those who were ctDNA negative. So, I want to repeat that, at a longer follow-up, which Dr. Dyrskjøt will be presenting, ctDNA positive patients without pathologic complete response had significantly lower recurrence-free survival and overall survival compared to ctDNA negative patients. Furthermore, ctDNA status at baseline, which is before neoadjuvant chemotherapy and before cystectomy, was a better predictor of recurrence-free survival compared to pathologic complete response, which is a remarkable finding here, although it's a smaller data set. Dr. Jeanny Aragon-Ching: Agree completely, Neeraj. So, I think the importance here, too, is upon prospective validation in larger data sets, we will find that a negative ctDNA test would help in identifying patients who can benefit more from bladder-sparing strategies. Neeraj, any final thoughts before we wrap up the podcast today? Dr. Neeraj Agarwal: Before I share my final thoughts, Jeanny, I would like to thank you for joining us and sharing your insights. I always find them very valuable. So, thank you so much for taking the time. I would like to wrap up the podcast by saying we are seeing an explosion in the development of novel therapeutic approaches for our patients with genitourinary cancers. At the 2023 ASCO GU meeting, we will have multiple studies with practice-impacting data presented by investigators from around the world. I urge our listeners to come and join us in the meeting not only to celebrate these successes but also to help disseminate these cutting-edge data to practitioners and maximize the benefit for our patients across the globe. I would like to thank our listeners for joining us today. You will find links to the abstracts which we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaimms Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, AstraZeneca/MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb , Astellas/Seattle Genetics Travel, Accommodations, Expenses: Dendreon, Algeta/Bayer, Bristol Myers Squibb, EMD Serono, Astellas Pharma
Preached for the Sixth Sunday after the Epiphany (2023-02-12). Readings: Deuteronomy 30:15-20 | 1 Corinthians 3:1-9 | Matthew 5:21-37 | Psalm 119:1-8
Bridget Gleason, previously Chief Sales Officer at Silk, is now an Advisor for the company and is also the Chief Revenue Officer at Util. In this episode, Andy turns the hosting duties to Bridget to discuss his book, Sell Without Selling Out. They talk about being intentional in the steps that you take as a seller, knowing when to do something different, understanding the value that you can bring to your buyers, and other insights and key points in the book. HIGHLIGHT QUOTES You need to have the courage to try and do something different - Bridget: "We want salespeople who are accountable. I've always thought 'I don't want to be accountable to your way if I don't think it's right.' If you're telling me to do a certain way and I'm accountable for the results, that's a hard no." Shaping generosity to help buyers achieve what's important to them - Andy: "It's also about helping them develop this vision of what success means for them. If you can play a role because you've built this trust-based relationship and play a role in helping shape this vision, you're influencing the choices they make." Find out more about Bridget in the links below: LinkedIn: https://www.linkedin.com/in/bridgetlgleason/ Website: https://www.principalpost.com/in-brief/bridget-gleason More on Andy: Connect on LinkedIn Get Andy's new book "Sell Without Selling Out" on Amazon Learn more at AndyPaul.com Sponsored by: Revenue.io | Unlock exponential growth with an AI-powered RevOps platform | Revenue.io Scratchpad | The fastest way to update Salesforce, take sales notes, and stay on top of to-dos | Scratchpad.com Blueboard | World's leading experiential rewards & recognition platform | Blueboard.com Explore the Revenue.io Podcast Universe: Sales Enablement Podcast Selling with Purpose Podcast RevOps Podcast
You are sure to be encouraged by the testimonies in this episode! If you are, share with a friend! •Justin C. Gleason Podcast link: https://podcasts.apple.com/us/podcast/justin-c-gleason/id1497594937
HeightsCast: Forming Men Fully Alive
As teachers and parents, it is often difficult to find the balance between leniency and strictness, love and fear. Getting the right tone, being firm in principle and flexible in preference, is indeed an art and an especially difficult one. While nothing can replace personal experience for growing in this art, self-reflection is a great aid to this end. This week on HeightsCast, Mr. Colin Gleason, Head of the Lower School, offers an aid to our personal reflection. The episode features a presentation by Mr. Gleason from our recent Art of Teaching Conference. At that conference, he spoke to seventy men from across the United States and beyond about how we, as teachers, can foster an environment of respectful dominion in the classroom. Colin offers a list of twelve principles, together with a great many practical pointers and delightful anecdotes. In the end, the point of discipline is to foster the right tone for learning, the proper culture for growth. Whether this growth occurs in the home or in the classroom, having the right tone is ultimately about love. Rome, they say, was not loved because she was great; she was great because she was first loved. So too our sons and students. Chapters 2:25 Beginning with the end 3:50 A question of balance 6:35 Principle #1: Discipline begins before class begins 8:32 Principle #2: Best disciplinary tool is a good lesson plan 12:25 Principle #3: Fostering class culture is more effective than listing class rules 14:40 Principle #4: We earn capital outside to spend inside 17:05 Principle #5: Smiling isn't enough; we need to laugh 19:45 Principle #6: Let them love what they see and fear what they don't 24:45 Principle #7: Don't confuse personal preference with principles 25:40 Principle #8: Non-correction corrections 27:35 Principle #9: Replace star stickers with handshakes 29:15 Principle #10: Learners over lessons 31:25 Principle #11: Replace line-writing with push-ups 34:30 Principle #12: When you send students to the principal's office, your authority goes with them Also on the Forum Boys, Education, and The Heights with Alvaro de Vicente Raising Contemplative Sons: The Problem with Boys with Colin Gleason Our Little Protectors: How Do WE See Our Boys? with Alvaro de Vicente On Recess: The Benefits of Free Play with Colin Gleason Toughness for the Adolescent Boy by Kyle Blackmer Seeing Our Boys with Loving Eyes: Not Projects, but Persons with Tom Royals Why Boys Need to Be Given Freedom by Andy Reed Material Order and the Middle School Boy with Kyle Blackmer Can I Catch It?: On Handling Wildlife with Eric Heil *For lyrics and history of the Ave Regina Caelorum, please visit adoremus.org.
Wielder of the Witchblade or not, Sara Pezzini's seen better days. In this Season I bonus episode, we find her in the most compromised of positions, namely, comatose. As Internal Affairs officer Gleason tries to figure out what happened to her, we get to see every stereotype you could ever imagine about an NYPD officer, right here in Witchblade #80! Bonus Episodes of Me & my friend, Pete can be found at Patreon.com/HSPP
A bear hunt with a handful of disabled Veterans in camp changed the trajectory of Otto Reetz's life forever. Not a Veteran himself, Reetz sat around a fire with a group of men several years ago and left that week knowing that he wanted to make a difference in the lives of those who serve and have served our country. As a result of that trip, Wounded Warriors United was founded and now puts on similar experiences around the country for Veterans and Active Duty Service Members from our home state of Wisconsin.Retiring after years in the construction business, Otto and his wife moved to Gleason in northern Wisconsin to a farm on a dead end country road. Now utilizing that farm as a retreat for those they serve, the Reetzs continue to expand their mission by partnering with passionate groups and individuals in The Badger State. I was introduced to Otto from mutual friend and Wisconsin National Guardsman Peter Thies. Both Thies and his brother have been active supporters of Wounded Warriors United for years, putting on various fundraisers to help fund hunting and fishing excursions for their brothers and sisters in arms.A lifelong outdoorsman, Reetz has a deep appreciation for the outdoors and just how meaningful these trips are to those who need them the most. We talked about a few special hunts that have created memories for not only the Veterans and their families but for Otto as well. Seeing the impact of his work has only fueled his passion and the future is bright for WWU with some exciting things on the horizon in 2023 and beyond.As with any nonprofit organization, Wounded Warriors United is always looking for new partnerships with the betterment of those they serve as the foundation for that connection. If you would like to join Otto and Vickie on their mission, or participate in one of their trips, visit www.woundedwarriorsunitedwi.orgYou can also follow them on Facebook.For more information about HHAUSA and how you can support our mission, visit www.hhausa.orgTo purchases HHAUSA hats, shirts, challenge coins and tumblers, visit www.hhasports.com
In this episode of BackTable Urology, Dr. Aditya Bagrodia interviews Dr. David Penson, professor and chair of urologic oncology at Vanderbilt University, about the indications and benefits of surgery for high risk prostate cancer. --- SHOW NOTES First, Dr. David Penson gives the traditional definition of high-risk prostate cancer, which is a PSA level over 20 ng/mL, a Gleason grade greater than 10, and a cancer staged at T2 or higher. However, he notes that in recent years, a more heterogeneous criteria has developed, so some patients with a Gleason grade greater than 8 and a T3 stage can also be considered high risk. Dr. Penson believes that pathological analysis is the best criteria to use when assessing risk and also uses MRI to distinguish between T2 and T3 patients and look for the median lobe before surgery. In his personal experience, he has noted that some patients will find online information about prostate cancer as a relatively benign chronic disease. For patients with high risk cancer, it is important to emphasize that the conventional active surveillance approach for low risk prostate cancer will not be beneficial. Both doctors agree that sending their patients curated, quality information is important and recommend using the WellPrept app. The doctors also discuss different imaging modalities involved in staging, such as PSMA PET scan, a bone scan, and prostate MRI. Before surgery, patients may receive neoadjuvant treatment. In the past, GnRH agonists were used, but long term data showed that patients receiving this type of therapy in addition to surgery had the same recurrence rate as patients who underwent surgery alone. Recently, newer neoadjuvant treatments, like PARP inhibitors, have been developed. Next, Dr. Penson speaks about choosing surgery versus radiation therapy (RT) as a primary treatment. The main risk of prostatectomy is its impact on continence and sexual dysfunction. The downside of radiation therapy is that the possibility of surgery as a therapeutic option is eliminated and its side effects, such as irritating urinary symptoms. Dr. Penson also notes that nerve sparing prostatectomies may be cancer sparing. In his opinion, if patients have impotence at baseline, nerve sparing surgery is not beneficial because of the risk of leaving positive margins. Contraindications to surgery include rectal involvement, a history of multiple abdominal surgeries, severe heart disease, bladder neck involvement, and a high volume nodal disease. Ideal prostatectomy patients are ones who have high grade disease contained in the prostate (T2) and patients with preexisting lower urinary tract symptoms (LUTS). Finally, the doctors discuss the use of nomograms to determine the extent of cancer control and the need for additional therapy. Dr. Penson has limited use for nomograms. He believes that they can generally be used to predict mortality, but not cure rates. He prefers to base prognosis on postoperative results. If the postoperative pathology report comes back with widely positive margins or bladder neck involvement, he discusses RT as an adjuvant treatment with his patients. For this reason, he emphasizes the need for collaboration with radiation oncologists and multidisciplinary tumor boards. --- RESOURCES WellPrept App: https://wellprept.com/
Preached for the Fourth Sunday after the Epiphany (2023-01-29). Readings: Micah 6:1-8 | 1 Corinthians 1:18-31 | Matthew 5:1-12 | Psalm 15
The Christian Leader Made Simple Podcast with Ryan Franklin
Rev. Stan Gleason, Senior Pastor of The Life Church and Assistant General Superintendent of the UPCI, and Ryan sit down to discuss his recent book The Unflawed Leader: Creating a Culture of Christlike Wellness in the Local Church. They discuss some amazing nuggets within the book, including topics on humility, leadership blind spots, culture, self-care, and so much more. This interview is loaded with wisdom from a tremendous man of God. The Unflawed Leader can be purchased at any major distributor including Amazon. It is available in print and kindle. Work with me (1:1 Executive Coaching): ryanfranklin.orgThe Christian Leader Blueprint (Free): ChristianLeaderMadeSimple.comYoutube/ Blog/ Podcast: ChristianLeaderMadeSimple.comConnect with me: Email: email@example.comFacebook: @rnfranklinTwitter: @rnfranklinInstagram: @rnfranklin#christianleadermadesimple, #ryanfranklin, #leadershippodcast, #leadershipyoutube, #christianleader, #leadership, #thoughtleadership, #ministry, #pastor, #pastors, #churches, #leadershiptraining, #churchleader, #churchleaders, #influence, #leadershipdevelopment, #coaching, #executivecoach, #leadershipcoaching, #productivitycoach, #productivity, #growthmindset, #theproductiveleader, #emotions, #thechristianleaderblueprint, #socialintelligence, #discipline
Preached for the Third Sunday after the Epiphany (2023-01-22). Readings: Isaiah 9:1-4 | 1 Corinthians 1:10-18 | Matthew 4:12-23 | Psalm 27:1, 5-13
Our Next Guest Michael Chieffo has been in just about all hit TV shows and many movies. He has been Hollywood's Go To Character actor since the 1980s and has appeared in Better Call Saul, Mad Men, Roswell, The A Team, Dallas, The Closer, Criminal Minds, Beverly Hills 90210, movies like Disclosure, L.A. Confidential, Gleason, Fully Realized Humans and the list goes on and on and on.Find out everything that goes on into a Hollywood Actor's career and life. We also talk about his days at Juilliard, his artwork that he is very passionate about, his wife and daughter who also work in Hollywood and much more.This is an inside look at one of the most talented Character actors of our time and it shows given his resume.Here is Michael's website where you can find out about his art and more about him.freedomboundart.comHere is his imdb page too so you can find out about all the work he has done in TV and Films.https://www.imdb.com/name/nm0157297/?ref_=nv_sr_srsg_0Grab a Mark 2.0 SHIRT and other MERCH- https://daddy-brians-merch-2.creator-spring.com/Mark 2.0 is the ultimate podcast for Music, TV, Movies, other entertainment and social media guests. Be sure to click that subscribe button for more great podcasts and check our other podcasts. We are on YouTube and all audio podcast platforms.-----------------------------------------------------------------------------------follow us on all SOCIAL MEDIAINSTAGRAM- https://www.instagram.com/mark2.0_podcast/TIK TOK- https://firstname.lastname@example.orgTWITTER- https://twitter.com/M20podcastFACEBOOK- https://www.facebook.com/mark2.0podcastofficial------------------------------------------------------------------------------------
For the first time ever, Caitlin & Sue do live coaching here on the podcast! Listen as they coach their friend, client and fellow businnes owner, Diana Gleason, about how to prioritize her health as she approaches 40. More about Diana Gleason: Every business should have someone watching its numbers- Who's watching yours?Coined the judgement free bookkeeper, Diana Gleason launched DG Consulting Services inside of the COVID-19 pandemic. Nationally established, Diana, helps creatives in business put organization around their internal bookkeeping and accounting practices. Diana truly believes the numbers tell the story of your business. She works alongside business owner's serving as their CFO and finance coach, while empowering them with their numbers to help them grow the business of their dreams.Diana's consistent work ethic, reliability, and upbeat attitude that anything is possible has made her a sought-out leader within her industry.Website: www.dianagleason.com Instagram: https://www.instagram.com/dg.consulting.servicesMeet your hosts:Sue McCarroll is the founder of Opal Wellness Studio and Caitlin Hatzenbuhler is the founder of Conscious Core. Caitlin and Sue have their unique styles of coaching women to increase self-care, self-compassion, navigate busy mom life and nourish their bodies mentally, emotionally, and physically. You can learn more about Sue at https://www.instagram.com/opal_wellness_studio/and Caitlin at https://www.instagram.com/conscious_core_caitlinThank you for listening! Please take a moment to subscribe and review.This supports the Well2You Podcast in reaching more people who need to be connected to these impactful conversations.https://podcasts.apple.com/us/podcast/well2you-podcast/id1547156150?i=1000504170074 https://open.spotify.com/show/7AE1vZFmBoxPvYfn5Abr1T?si=RjrXrOWoToKvZ5bmCcJSgw https://www.well2you.org/well2you-podcast
Scott Eggener, MD, University of Chicago, and Jonathan Epstein, MD, The Johns Hopkins Medical Institutions, join the show to debate whether Gleason Score 6 prostate cancer should be renamed to non-cancer. The trio hit on what should happen upon diagnosis and Gleason grade 6, which patients should be offered active surveillance, the benefits and risks of not calling this diagnosis “cancer,” how often and how frequently to biopsy, overscreening, and many other discussion points. Read Dr. Eggener's editorial in the Journal of Clinical Oncology. https://ascopubs.org/doi/full/10.1200/JCO.22.00123 Read Dr Epstein's response in the Journal of Clinical Oncology. https://ascopubs.org/doi/full/10.1200/JCO.22.00926 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
Episode 306 - Darold Gleason, Bernie Schultz and Ish Monroe
Boardroom Governance with Evan Epstein
0:00 -- Intro.1:31 -- Start of interview.1:57 -- Peter's "origin story". 2:40 -- His career prior to NACD, including at Institutional Shareholder Services (ISS). Peter joined NACD in 2000.4:52 -- On the origin and mission of the National Association of Corporate Directors (NACD). Founded in 1977 by John Nash. Today the organization has grown to 23,000+ members. 7:02 -- About the NACD Directorship Certification (created three years ago). About 2,800 candidates have registered, and about ~1,100 have graduated with the certification.10:38 -- On the evolution of corporate governance in the last 30 years from his vantage point. “Everything has changed [about boards] – it used to be more of an honorary position, we look it now as a profession with accountability and expectations.” The precedent of the ISS corporate governance quotient (CGQ).14:36 -- About NACD's Future of the American Board Report: A Framework for Governing into the Future. 20:07 -- On NACD's Summit 2022 and lessons from 2022 from a corporate governance perspective. The impact of the pandemic and getting back to in-person events.24:29 -- About NACD's 20 chapters throughout the US. Mostly in "NFL cities."27:53 -- On ESG and the anti-ESG trend and the politicization of corporation governance.30:30 -- On Institutional Investors passing-through voting power to beneficial owners, retail investors and the Universal Proxy Rule. A revolution in shareholder democracy?41:01 -- On the increasing influence of private markets and its corporate governance implications. "From NACD's 23,000 members, about 8,000 are directors of private companies." There is a lot of informationsharing between public and private company directors.43:49 -- On the challenges of founder-led private companies. The case of FTX.47:20 -- On dual-class share structures (supermajority voting structures). "The NACD doesn't have an official position." The example of Meta and Mark Zuckerberg. On the role of the board in non-profits. "I always recommend to go get a few independent directors for boards, because they will tell you what they are thinking (unvarnished opinions) but you have to listen to their independent advice."52:10 -- Focus on social issues (pressure on CEOs speaking out). The framework that CEOs and boards must use to communicate their positions.55:39 - The books that have greatly influenced his life: Good to Great, by Jim Collins (2001)To Kill a Mockingbird, by Harper Lee (1960)The Industries of the Future, by Alec Ross (2016)57:17 - His mentors, and what he learned from them. His parents.Ken Daly, former CEO of NACD from 2007-2017.Ira Millstein59:32 - Quotes he thinks of often or live his life by. "If at first you don't succeed, try, try again." (from his parents)"It ain't about how hard you hit. It's about how hard you can get hit and keep moving forward." Rocky Balboa."Man in the Arena" by Teddy Roosevelt (1910).1:00:59 - An unusual habit or an absurd thing that he loves: he watches TV to unwind (noise in the background).1:01:52 - The living person he most admires: his mother and his wife.Peter Gleason is the President and CEO of the National Association of Corporate Directors (NACD).__ You can follow the NACD on social media at:Twitter: https://twitter.com/NACDLinkedIn: https://www.linkedin.com/company/national-association-of-corporate-directors/YouTube: https://www.youtube.com/user/NACDVideos1__ You can follow Evan on social media at:Twitter: @evanepsteinLinkedIn: https://www.linkedin.com/in/epsteinevan/ Substack: https://evanepstein.substack.com/__Music/Soundtrack (found via Free Music Archive): Seeing The Future by Dexter Britain is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License
On this episode of the I See Dead Plants podcast, host Ed Zaworski Interviews Dr. Mark Gleason, Professor at the plant pathology, entomology, and microbiology department at Iowa State University. Dr Gleason and Ed discuss the cucurbit pests and research being done to help mitigate these issues. Additional Resources https://www.cucurbit.plantpath.iastate.edu/ How to cite the podcast: Zaworski, E. (Host), Gleason, M. (Interviewee). Tunneling Away from Pests: Cucurbit Pests and Ways to Control Them S2:E4 (Podcast). 01.04.23. In I See Dead Plants. Crop Protection Network. https://five.libsyn.com/episodes/view/25504173
Rick Podell and I discuss his early influences; Jackie Gleason; Ed Sullivan; 50's and 60's standups; Alan King; doing standup for his dog; tap dancing; leaving college to do Dames at Sea off Broadway; getting hired as a Universal contract player; doing Baretta and getting a mentor in Robert Blake; Busting Loose; Garry Marshall; Paramount commissary; Chopped Liver Brothers; how appearing on the Mike Douglas Show makes you crave for new material; how his jack-of-all trades style hurt him; working with Milton Berle in Two by Two and meeting his endowment; Budd Friedman gets roasted; writing the pilots Brothers and Our Time with co-writer Mike Preminger; starring in films "Lunch Wagon" and "Underground Aces"; co-starring in "Hero at Large" with John Ritter; losing out on Chips to Erik Estrada; performing with Richard Lewis, Rich Hall, and Dana Carvey; Jay Leno saying he was too handsome to be a successful comedian; touring Montana with Gilbert Gottfried; guest starring as Jackie Jackerman on a memorable Family Ties; guest starring as a mohel on Cheers; writing the screenplay for "Nothing in Common" about his relationship with his dad; having Tom Hanks and Jackie Gleason star; receiving letters from people with the same situations; the film being perceived as too Jewish; Gleason's ill-health; opening with Ginger Rogers for a year; opening for Cher; working on Sunset Boulevard on Broadway with Andrew Lloyd Webber and Glenn Close; being directed by someone who directed Ronald Reagan and Clark Gable; working and later teaching at the Beverly Hills Playhouse; cell phones; and his one-man show
In this episode, we interviewed Andrew Gleason, president of the Foothills Trail Conservancy. The Foothills Trail is a 75 mile hiking trail that goes from Table Rock State Park to Oconee State Park. Thousands of people hike it every year, including many who through-hike the entire distance. Andrew tells us about the origins and history of the trail, some of the best parts to hike, how to deal with bears, and how to support the trail.You can learn more about the conservancy here:https://foothillstrail.org/You can view the entire interactive map of the trail, which Andrew created, here:https://www.google.com/maps/d/u/0/viewer?fbclid=IwAR1QV0s0b_Rwbi_B9azlnpxnqPYbrz9biARQO8gBNdjpBySQaYrpqHxiVKc&mid=1ayrDOGS1DQ7O5yCflxafByKWnYS_6RNn&ll=34.98064322270275%2C-82.94218361714363&z=12To see a video version of this episode which includes photos of many of the sites mentioned in the interview, click here: https://youtu.be/vc265w03W1IPlease visit our website at www.gocarolinas.net#gocarolinas#FoothillsTrail#Hiking#TableRockStatePark#OconeeStatePark
Range of Richfield president Jim Babiasz announces January classes and events at the Range. (therangewi.com) Huntworth Gear pro staffer Bernie Barringer, of Brainerd, Minn., talks about his 2022 hunting season and offers advice for staying warm outdoors in the coldest weather. (huntworthgear.com, youtube.com) Otto Reetz, founder of Wounded Warriors United of Wisconsin, tells us why he started this non-profit and how he's raising funds to build a dream retreat for veterans and their families at Country Haven Farm in Gleason, Wis. He invites listeners to attend an ice fishing fundraiser January 28 at the Lure Bar on the Petenwell Flowage. (woundedwarriorsunitedwi.org, facebook.com/hardwaterfreak/s, barnumbaymarina.com) In the Madison Outdoors Report, pro angler Duffy Kopf warns anglers to wait until the ice is thicker before ice fishing on the Madison Chain. He also announces classes at the 20th annual Muskie School, March 25 at Waunakee High School (capitalcitymuskiesinc.org/muskie-school/)
SURPRISE! Here's a (post) Christmas special episode! The Gleason brothers along with Florida Santa Phil Jacques discuss their own journeys since the last show, the destruction of some tracks, the revival of others, and why certain divisions look a certain way. Find us on Instagram @makinglapspodcast, Facebook.com/makinglapspodcast, and send us some feedback to email@example.com or have your voice heard over at Anchor.fm/makinglaps and selecting the voice mail option!
Jay Santos and sub commander Gleason are checking vax cards …..and peoples breath. Steve Bosell uses a new stage name for his comedy act at the kids school. Sign up for a Backstage Pass and enjoy a 30,000 plus hour archive, Phil's new podcast, Classic podcasts, Bobbie Dooley's podcasts, special live streaming events and shows,and oh so very much more… Sign up now at PhilHendrieShow.com!
Preached on Christmas Eve (2022-12-24). Readings: Isaiah 9:2-7 | Titus 2:11-14 | Luke 2:8-20 | Psalm 96
In this episode of the I See Dead Plants Podcast, we are joined by Dr. Mark Gleason to discuss the smart apple sprayer and how it helps reduce the amount of pesticides needed to control common apple diseases. Additional Resources https://www.smartapplespray.plantpath.iastate.edu/ https://www.smartapplespray.plantpath.iastate.edu/smarter-apple-spraying-podcast How to cite the podcast: Zaworski, E. (Host), Gleason, M.Interviewee). Outthinking Apple Diseases: The Smart Apple Sprayer S2:E3 (Podcast). 12.21.22. In I See Dead Plants. Crop Protection Network. https://sites.libsyn.com/416264
Paddy Gleason is a professional paintball player for Seattle Thunder and the strength and conditioning coach for the Major League Rugby team, Seattle Seawolves. His story is vulnerable and real, and one many can relate to. Paddy's climb to the top is full of adversity and strength which makes this one of the more special shows to date. Get access to our discord here: https://www.patreon.com/playthegamepodcast?fan_landing=truePTG SHOW SPONSORS:LONE WOLF PAINTBALL: https://www.lonewolfpaintball.comHK ARMY: https://www.hkarmy.com/TRANZFUSE: https://tranzlabs.com/?ref=PLAYTHEGAM...ICONIC PAINTBALL: https://www.iconicpaintball.com/David Roque: CPA Assistant AHSBIZ@GMAIL.COMSupport the show
Preached for the Fourth Sunday of Advent (2022-12-18). Readings: Isaiah 7:10-16 | Romans 1:1-7 | Matthew 1:18-25 | Psalm 80:1-7, 16-18
When archaeologists Eric Gleason and Jacqui Cheung bought a run-down building in The Dalles' downtown in 2000, they had a vague sense of its history. 210 E. 1st St. was simply known as “the Chinese building,” having operated as a Chinese laundry and merchandise store from the late 1800s to the 1920s. But the building had long since fallen into disrepair, and information about its owners and occupants proved elusive. Gleason and Cheung's renovations and research over the last 20 years have revealed a deeper history of the Wing Hong Hai Company store — and the small but vibrant Chinatown that surrounded it. The artifacts and documents they've uncovered offer a glimpse of what life may have been like for Asian immigrants who came to The Dalles 150 years ago. Gleason and Cheung join us for a tour of the building and to share some of those insights.
Research To Practice | Oncology Videos
Featuring perspectives from Prof Karim Fizazi and Prof Stéphane Oudard, including the following topics: Introduction: Journal Club — Karim Fizazi, MD, PhD and Stéphane Oudard, MD, PhD (0:00) Case: A man in his late 50s with Gleason 7 prostate cancer after prostatectomy/radiation therapy/androgen deprivation therapy (ADT) experiences biochemical recurrence 2 years later (PSA 0.5; doubling time 9 months) — Philip L Brooks, MD (10:58) Case: A man in his early 70s with a pacemaker presents with de novo metastatic hormone-sensitive prostate cancer (mHSPC) after cerebrovascular accident — Nasfat Shehadeh, MD (28:50) Case: A man in his late 40s with multiple medical comorbidities presents with de novo mHSPC (PSA 19.4) and responds to ADT/docetaxel — Gurveen Kaur, MD (47:00) Case: A man in his mid 60s with de novo mHSPC receives leuprolide, and PSA levels decrease from 865 ng/mL to 1.34 ng/mL — Joanna Metzner-Sadurski, MD (50:38) Case: A man in his late 50s with mHSPC receives leuprolide, experiences disease progression 1.5 years later and responds to abiraterone/prednisone but on liquid biopsy is found to have an AR T878 mutation — Niyati A Nathwani, MD (54:30) Case: A man in his mid 60s presents with de novo metastatic prostate cancer and experiences disease progression on ADT + docetaxel, now with progressive disease on abiraterone/prednisone; germline CHEK2 mutation — Syed F Zafar, MD (56:51) CME information and select publications
There can be few writers more deserving of Backlisted's attention than the Irish writer, Maeve Brennan. An adopted New Yorker, Brennan died there in 1993 and was by that time so thoroughly forgotten in her native land, that she received no obituaries in any Irish papers. We are joined by the writers Sinéad Gleason and David Hayden to discuss her collection, The Springs of Affection – subtitled ‘stories of Dublin' – which was first published posthumously by Houghton Mifflin in 1997, although all but one of these first appeared in the New Yorker, where Brennan was a staff writer for twenty-seven years. It was the enthusiastic praise from other writers including Alice Munro, Edna O'Brien and Mavis Gallant among others, that helped get The Springs of Affection the kind of international attention that the two collections published in Maeve's lifetime failed to achieve. Since then, Maeve Brennan's reputation has grown steadily, and her stories are now regularly and favourably compared to those of Joyce, Chekov and Colette. In Ireland, in particular, she has won the admiration of a new generation of women writers, who in Anne Enright's phrase, see her as ‘a casualty of old wars not yet won.' This episode also features Andy revisiting the Linda Nochlin's classic 1971 essay, Why Have There Been No Great Women Artists? while John is impressed by Orlam, P.J. Harvey's dark and brooding verse novel, written entirely in Dorset dialect. Timings: 08:44 - Why Have There Been No Great Women Artists? by Linda Nochlin 16:16 - Orlam by P.J. Harvey 22:46 - The Springs Of Affection By Maeve Brennan * To purchase any of the books mentioned in this episode please visit our bookshop at https://uk.bookshop.org/shop/backlisted where all profits help to sustain this podcast and UK independent bookshops. * For information about everything mentioned in this episode visit www.backlisted.fm * If you'd like to support the show, receive the show early and get extra bonus fortnightly episodes, become a Patreon at https://www.patreon.com/backlisted
“Nobody's gonna know. They're gonna know.”If you've been on TikTok in the past year, you're most likely familiar with these two sentences, first drolly uttered in a post by TikTok creator Chris Gleason in 2020. The post has become a hit and has been viewed more than 14 million times.But the sound is more famous than the video.When uploading a video to TikTok, the creator has the option to make that video's audio a “sound” that other users can easily use in their own videos — lip-syncing to it, adding more noise on top of it or treating it like a soundtrack. Gleason's sound has been used in at least 336,000 other videos, to humorous, dramatic and sometimes eerie effect.The journalist Charlotte Shane delves into the world of repurposed sounds, exploring how TikTok and other apps have enabled, as she writes in her recent article for The Times, “cross-user riffing and engagement, like quote-tweeting for audio.” She also considers “what makes a sound compelling beyond musical qualities or linguistic meaning.”While “brainfeel” may be an apt buzzword for the sensation audio memes elicit, Ms. Shane writes, it is more than a mere trend: We have entered the “era of the audio meme.”This story was written by Charlotte Shane and recorded by Audm. To hear more audio stories from publications like The New York Times, download Audm for iPhone or Android.